Skip to content
IRONXPEPTIDES
5-AMINO-1MQ 5MG research vial, Iron Peptide Research label
Metabolic & Incretin

5-Amino-1MQ

Also known as 5-amino-1-methylquinolinium, 5A1MQ, NNMTi

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme linked to fat tissue metabolism and NAD+ levels. It has been studied in mouse models of obesity and muscle aging.

Preclinical research

Size

3 options
Catalog no.
5AM
Specification
5mg *10 vials
Per kit
10 vials
PricePricing will be published soon

For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.

Overview

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide. It came from structure-activity studies of quinolinium compounds by researchers at the University of Texas Medical Branch, who designed the series to block NNMT, an enzyme overexpressed in white adipose tissue in obesity. In vitro, 5-amino-1MQ was membrane-permeable and did not inhibit related methyltransferases or NAD+ salvage enzymes. Rodent studies have examined obesity, liver fat, and aged skeletal muscle. No human trials have been reported in the indexed literature.

Class: Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor

Mechanism of action

How the compound acts, as described in the literature.

  1. NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA). This consumes SAM and diverts nicotinamide away from NAD+ salvage.

  2. In adipocytes, 5-amino-1MQ and related inhibitors lowered intracellular 1-MNA, raised NAD+ and SAM, and suppressed lipogenesis.

  3. In diet-induced obese mice, NNMT inhibition reduced body weight, white fat mass, and adipocyte size without reducing food intake. Later work reported improved glucose tolerance, insulin sensitivity, and liver fat.

  4. In aged mice, NNMT inhibition activated senescent muscle stem cells and was associated with larger muscle fibers and greater contractile force after injury, along with shifts in NAD+/NADH redox state.

Published research

Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.

Evidence & safety

What the research does not show, and the adverse events and regulatory status it reports.

All published evidence comes from cell and rodent studies; no human safety, pharmacokinetic, or efficacy data are indexed on PubMed. Most studies come from a single group of investigators, including authors affiliated with the company Ridgeline Therapeutics, and have not been independently replicated. 5-Amino-1MQ is not an approved drug.

Specifications

All sizes, exactly as catalogued.

Catalog no.ProductSpecificationVials per kit
5AM5-Amino-1MQ5mg *10 vials10
10AM5-Amino-1MQ10mg *10 vials10
50AM5-Amino-1MQ50mg *10 vials10

For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.

More in Metabolic & Incretin